Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Assessment and Market Forecasts to 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global COPD market. The report identifies the key trends shaping and driving the global COPD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global COPD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the Chronic Obstructive Pulmonary Disease (COPD) market to be worth $8.4 billion in 2009 and projects it to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to reach $12.2 billion in 2017. The development of novel once-daily inhaled therapies is expected to provide new treatment options for COPD patients worldwide, and will play a major role in the expansion of the COPD market in the coming years. A steady increase in the incidence rate, the smoking population and in injurious environmental factors in most countries has caused the COPD market to grow significantly.

Scope

The report provides information on the key drivers and challenges of the COPD market. Its scope includes:

Annualized global COPD market revenues data from 2001 to 2009, forecast for eight years to 2017.
Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as long-acting beta2 agonists, long-acting muscarinic antagonists, long-acting beta2 agonist and inhaled corticosteroid combinations, Inhaled Long-acting beta 2 Antogonist, PDE4 inhibitors and p38 kianse inhibitors.
Analysis of the current and future competition in the global COPD market. Key market players covered are GSK, Almirall S.A., Novartis AG, AstraZeneca and Pfizer Inc.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the COPD therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global COPD market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global COPD market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What’s the next big thing in the global COPD market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE INTRODUCTION

2.1 GlobalData Pipeline Report Guidance

3 CHRONIC OBSTRUCTIVE PULMONARY DISEASE – MARKET CHARACTERIZATION

3.1 Overview
3.2 COPD Market Size
3.3 COPD Market Forecast and CAGR
3.4 Drivers and Barriers for the COPD Market
  3.4.1 Drivers for the COPD Market
  3.4.2 Barriers for the COPD Market
3.5 Opportunity and Unmet Need
3.6 Key Takeaway

4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET : COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the COPD Market
  4.3.1 Spiriva HandiHaler (Tiotropium bromide inhalation powder)
  4.3.2 Brovana (Arformoterol)
  4.3.3 Foradil Aerolizer (formoterol fumarate inhalation powder)
  4.3.4 Symbicort (budesonide/formoterol fumarate dihydrate) 160/4.5 µg
  4.3.5 Advair Diskus (fluticasone propionate and salmeterol inhalation powder)
4.4 Key Takeaway

5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET : PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
  5.2.1 Technology Trends Analytic Framework
5.3 COPD Therapeutics – Promising Drugs Under Clinical Development
5.4 Molecule Profile for Promising Drugs Under Clinical Development
  5.4.1 Aclidinium Bromide
  5.4.2 Daxas (roflumilast)
  5.4.3 Indacaterol Maleate (QAB149, Onbrez Breezhaler)
  5.4.4 NVA237 (Glycopyrronium Bromide)
5.5 COPD Market – Clinical Pipeline by Mechanism of Action
5.6 COPD – Pipeline by Clinical Phases of Development
  5.6.1 COPD Therapeutics – Phase III Clinical Pipeline
  5.6.2 COPD Therapeutics – Phase II Clinical Pipeline
  5.6.3 COPD Therapeutics – Phase I Clinical Pipeline
  5.6.4 COPD Therapeutics – Pre-clinical Pipeline
  5.6.5 COPD Therapeutics – Discovery Pipeline
5.7 Discontinued Drugs for COPD
5.8 Key Takeaway

6 CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET : IMPLICATIONS FOR FUTURE MARKET COMPETITION

7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET : FUTURE PLAYERS IN THE COPD MARKET

7.1 Introduction
7.2 GlaxoSmithKline plc.
  7.2.1 Company Overview
  7.2.2 Respiratory Disease Portfolio
7.3 Almirall S.A
  7.3.1 Company Overview
  7.3.2 Respiratory Disease Portfolio
7.4 Novartis AG
  7.4.1 Company Overview
  7.4.2 Respiratory Disease Portfolio
7.5 AstraZeneca
  7.5.1 Company Overview
  7.5.2 Respiratory Portfolio
7.6 Pfizer Inc.
  7.6.1 Company Overview
  7.6.2 Respiratory Disease Portfolio

8 CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET : APPENDIX

8.1 Market Definitions
8.2 Abbreviations
8.3 Research Methodology
  8.3.1 Coverage
  8.3.2 Secondary Research
  8.3.3 Forecasting
  8.3.4 Primary Research
  8.3.5 Expert Panels
8.4 Contact Us
8.5 Disclaimer
8.6 Sources

LIST OF TABLES

Table 1: COPD Therapeutics Market, Global, Revenue ($bn), 2001-2009
Table 2: COPD Therapeutics Market, Global, Revenue ($bn), 2009-2017
Table 3: Major Marketed Products Comparison in COPD Market, 2010
Table 4: COPD Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 5: COPD Therapeutics – Phase III Clinical Pipeline, 2010
Table 6: COPD Therapeutics – Phase II Clinical Pipeline, 2010
Table 7: COPD Therapeutics – Phase I Clinical Pipeline, 2010
Table 8: COPD Therapeutics – Pre-clinical Pipeline, 2010
Table 9: COPD Therapeutics – Discovery Pipeline, 2010
Table 10: List of Discontinued Drugs for COPD, 2010
Table 11: GlaxoSmithKline plc - Respiratory Disease Pipeline Products, 2010
Table 12: Almirall S.A– Respiratory Disease Pipeline Products, 2010
Table 13: Novartis AG– Respiratory Disease Pipeline Products, 2010
Table 14: AstraZeneca – Respiratory Marketed Products, 2010
Table 15: AstraZeneca – Respiratory Pipeline Products, 2010
Table 16: Pfizer Inc – Respiratory Disease Pipeline Products, 2010

LIST OF FIGURES

Figure 1: COPD Therapeutics Market Revenue ($bn) 2001–2009
Figure 2: Opportunity and Unmet Need in the COPD Market, 2010
Figure 3: Strategic Competitor Assessment of the Major Marketed Products for COPD, 2010
Figure 4: Technology Trends Analytic Framework of the COPD Pipeline, 2010
Figure 5: Technology Trends Analytic Framework of the COPD Pipeline - Description, 2010
Figure 6: COPD Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 7: COPD Pipeline by Phase of Clinical Development, 2010
Figure 8: Implications for Future Market Competition in the COPD Market, 2010
Figure 9: COPD Market – Clinical Pipeline by Company, 2010
Figure 10: GlobalData Market Forecasting Model

COMPANIES MENTIONED

GlaxoSmithKline plc.
Almirall S.A
Novartis AG
AstraZeneca
Pfizer Inc. Skip to top